IRIS
CORTELLINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.566
EU - Europa 1.648
AS - Asia 1.560
SA - Sud America 297
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 7.109
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.494
SG - Singapore 814
RU - Federazione Russa 499
IE - Irlanda 416
BR - Brasile 261
CN - Cina 242
VN - Vietnam 194
DE - Germania 182
HK - Hong Kong 153
IT - Italia 109
UA - Ucraina 88
FI - Finlandia 71
GB - Regno Unito 53
SE - Svezia 50
CZ - Repubblica Ceca 42
CA - Canada 41
NL - Olanda 34
JP - Giappone 28
PL - Polonia 28
TR - Turchia 25
MX - Messico 23
IN - India 22
FR - Francia 20
BD - Bangladesh 16
BE - Belgio 16
IQ - Iraq 16
ZA - Sudafrica 15
ES - Italia 12
AR - Argentina 10
ID - Indonesia 9
EC - Ecuador 7
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
CO - Colombia 4
EG - Egitto 4
IL - Israele 4
JO - Giordania 4
KE - Kenya 4
UZ - Uzbekistan 4
AL - Albania 3
AT - Austria 3
AZ - Azerbaigian 3
CL - Cile 3
EE - Estonia 3
EU - Europa 3
HN - Honduras 3
LT - Lituania 3
MA - Marocco 3
PT - Portogallo 3
VE - Venezuela 3
BG - Bulgaria 2
CH - Svizzera 2
KR - Corea 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PH - Filippine 2
PK - Pakistan 2
RO - Romania 2
RS - Serbia 2
SA - Arabia Saudita 2
TN - Tunisia 2
AU - Australia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GH - Ghana 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LU - Lussemburgo 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 7.109
Salva come PNG Salva come JPEG
Città #
Dallas 520
Chandler 430
Singapore 420
Dublin 416
San Jose 379
Ashburn 305
Jacksonville 305
Hong Kong 150
Santa Clara 143
Boardman 123
The Dalles 108
Council Bluffs 100
New York 99
Munich 77
Ho Chi Minh City 71
Beijing 64
Ann Arbor 61
Princeton 58
Lawrence 57
Los Angeles 56
Helsinki 47
Moscow 47
Wilmington 43
Brno 42
Amsterdam 33
Hanoi 32
São Paulo 28
Tokyo 28
Columbus 26
Warsaw 26
Bremen 21
Montreal 19
Dong Ket 18
Dearborn 17
Assago 16
Brussels 16
Frankfurt am Main 16
Stockholm 16
Atlanta 15
Brooklyn 15
Chicago 15
Denver 14
Falkenstein 14
San Francisco 14
Johannesburg 13
L'aquila 13
Orem 13
Turku 12
London 11
Izmir 10
Lappeenranta 10
Nanjing 10
Belo Horizonte 9
Brasília 9
Milan 9
Chennai 8
Da Nang 8
Mexico City 8
Phoenix 8
Rio de Janeiro 8
Seattle 8
Boston 7
Lauterbourg 7
Poplar 7
Guangzhou 6
Haiphong 6
Houston 6
Hải Dương 6
L’Aquila 6
Nanchang 6
Pune 6
Shanghai 6
Ankara 5
Berlin 5
Guayaquil 5
Hefei 5
Jakarta 5
Jinan 5
Manchester 5
Norwalk 5
San Mateo 5
Tianjin 5
Toronto 5
Amman 4
Asunción 4
Baghdad 4
Bauru 4
Cagliari 4
Campinas 4
Can Tho 4
Dhaka 4
Juneau 4
New Delhi 4
Oklahoma City 4
Querétaro 4
Redwood City 4
Rome 4
Woodbridge 4
Baku 3
Charlotte 3
Totale 4.877
Salva come PNG Salva come JPEG
Nome #
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 179
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 163
"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer 157
Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases 150
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 149
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 147
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 145
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 143
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 143
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 141
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 140
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice 139
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 136
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 136
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 134
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 134
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 132
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 130
Evaluation of prognostic factors for survival in transverse colon cancer 130
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients 128
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 125
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 124
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 122
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 121
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 120
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 120
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 120
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 119
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 117
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 117
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 116
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study 116
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 116
Cancer care after natural disaster: Different countries, similar problems 115
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 114
Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen 114
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 112
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 112
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 110
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 109
Rare bone toxicity associated with vismodegib 109
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 107
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 106
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 105
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 104
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 104
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 104
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 103
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 103
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 102
Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience 101
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 99
Studio sul ruolo della storia familiare di neoplasie come fattore predittivo surrogato per l'immunoterapia con inibitori dei checkpoint immunitari PD-1/PD-L1 94
Family history of cancer and DNA damage response genes: Two sides of the same coin? 88
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 85
Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report 83
"palliative" or "supportive": Is It Just a Matter of Word? 81
Practical Advices About How To Handle Disease Progression During Osimertinib In EGFR-Mutant NSCLC Patients: Is It The Same Old Story? A Mini Review 78
Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life 69
Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice 67
First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen 65
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 58
Totale 7.210
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.436
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.436
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202121 0 0 0 0 0 0 0 0 0 0 0 21
2021/2022209 4 1 16 8 11 4 3 19 23 2 23 95
2022/20231.193 65 95 9 148 88 114 2 89 516 6 43 18
2023/2024389 38 7 17 20 29 110 3 49 0 17 19 80
2024/20251.515 46 28 119 101 145 110 221 100 369 50 138 88
2025/20263.125 157 300 393 374 349 213 425 107 262 419 126 0
Totale 7.210